Ken Griffin Bridge Bio Pharma, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 313,000 shares of BBIO stock, worth $7.98 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
313,000
Previous 352,800
11.28%
Holding current value
$7.98 Million
Previous $10.9 Million
27.32%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding BBIO
# of Institutions
296Shares Held
176MCall Options Held
8.64MPut Options Held
2.81M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$791 Million45.4% of portfolio
-
Viking Global Investors LP25.1MShares$640 Million2.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$358 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$317 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$155 Million67.33% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.78B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...